CG Oncology, Inc. - 8-K Filing
CG Oncology reports positive Phase 3 PIVOT-006 topline data for cretostimogene showing 68% reduction in recurrence risk and updates BLA submission timelines. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CGON
Read the full article at SEC EDGAR
Part of the story CG Oncology, Inc. - 8-K Filing (3 articles)